Patents by Inventor J. Evan Sadler

J. Evan Sadler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fluorogenic substrate for ADAMTS13
    Patent number: 8663912
    Abstract: Disclosed are fluorogenic substrates for measuring ADAMTS13 activity or ADAMTS13 inhibitor activity. Substrates can comprise an oligopeptide which can consist of up to 80 amino acids of sequence of von Willebrand Factor (VWF). The oligopeptide can include modifications of sequence of VWF, including an amino-terminal glycine, a scissile Y-M peptide, and a cysteine substitution located from 1 to 12 amino acids from the scissile Y-M in the carboxy terminal direction. A substrate can further comprise a fluorophore and a fluorescence quencher bound to the oligopeptide on opposite sides of the scissile Y-M peptide, wherein the fluorescence quencher is not identical to the fluorophore. An oligopeptide can be encoded by a nucleic acid sequence which can also encode a His tag. An oligopeptide can be expressed in a cell or microorganism. Also disclosed are methods of using a fluorogenic substrate to measure ADAMTS13 activity or ADAMTS13 inhibitor activity.
    Type: Grant
    Filed: July 18, 2012
    Date of Patent: March 4, 2014
    Assignee: Washington University
    Inventors: J. Evan Sadler, Joshua Muia, Weiqiang Gao
  • FLUOROGENIC SUBSTRATE FOR ADAMTS13
    Publication number: 20130023004
    Abstract: Disclosed are fluorogenic substrates for measuring ADAMTS13 activity or ADAMTS13 inhibitor activity. Substrates can comprise an oligopeptide which can consist of up to 80 amino acids of sequence of von Willebrand Factor (VWF). The oligopeptide can include modifications of sequence of VWF, including an amino-terminal glycine, a scissile Y-M peptide, and a cysteine substitution located from 1 to 12 amino acids from the scissile Y-M in the carboxy terminal direction. A substrate can further comprise a fluorophore and a fluorescence quencher bound to the oligopeptide on opposite sides of the scissile Y-M peptide, wherein the fluorescence quencher is not identical to the fluorophore. An oligopeptide can be encoded by a nucleic acid sequence which can also encode a His tag. An oligopeptide can be expressed in a cell or microorganism. Also disclosed are methods of using a fluorogenic substrate to measure ADAMTS13 activity or ADAMTS13 inhibitor activity.
    Type: Application
    Filed: July 18, 2012
    Publication date: January 24, 2013
    Applicant: WASHINGTON UNIVERSITY
    Inventors: J. Evan Sadler, Joshua Muia, Gao Weiqiang
  • DNA clones of human placental plasminogen activator inhibitor
    Patent number: 5028534
    Abstract: cDNA clones having a base sequence for human placental plasminogen activator inhibitor (PAI-2) have been developed and characterized and the amino acid sequence of the PAI-2 has been determined. The PAI-2 protein has then been expressed in prokaryotic and eukaryotic cells.
    Type: Grant
    Filed: September 15, 1987
    Date of Patent: July 2, 1991
    Assignees: Washington Univ., Monsanto Company
    Inventors: J. Evan Sadler, Tze-Chein Wun
  • DNA clone of human thrombomodulin and portions thereof
    Patent number: 4912207
    Abstract: A cDNA having a base sequence for human thrombomodulin has been cloned and characterized and the amino acid sequence of the human thrombomodulin has been determined.
    Type: Grant
    Filed: May 6, 1987
    Date of Patent: March 27, 1990
    Assignee: Washington University
    Inventors: Philip W. Majerus, J. Evan Sadler